Vol 9, No 2 (2006)
Review paper
Published online: 2006-06-21
Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders
Nucl. Med. Rev 2006;9(2):147-153.
Abstract
In this article the role of molecular imaging with SPECT and
PET in patients with movement disorders is reviewed. It is mentioned
that SPECT and PET imaging with cocaine analogues
(123I-b-CIT,123I-FP-CIT, 18F-DOPA), radioligands labeling the presynaptic
dopamine transporters, is of value for the differentiation
of patients with PD or Parkinson-plus syndromes with individuals
with essential tremor. In addition the clinical impact of
this procedure, the role of molecular imaging in the preclinical
diagnosis and in the follow-up of patients with PD, as well as, in
the differential diagnosis between Alzheimer’s disease and
Lewy-body dementia, is evaluated. Finally, the clinical impact
of 123I-IBZM-SPECT imaging, a radiopharmaceutical which labels
the postsynaptic D2 receptors and the discrimination between
idiopathic PD and Parkinson-plus syndromes (multiple
system atrophy, progressive supranuclear palsy and corticobasal
ganglia degeneration), is mentioned.
Keywords: molecular imagingmovement disordersPETSPECTI-123-DaTSCANI-123-IBZM
